analysis of Canadian open-label studies
Ruth A Dickson 1* , Ellen Maki 2 , Christopher Gibbins 3 , Stephen W Gutkin 4 , Atilla Turgay 5 and Margaret D Weiss 3
Abstract
Background: The relatively short durations of the initial pivotal randomized placebo-controlled trials involving atomoxetine H[r]